AriBio Co., Ltd. announced that it will issue 5th series registered non-guaranteed private convertible bonds for proceeds of KRW 600,000,000 and 6th series registered unguaranteed private convertible bonds for the proceeds of KRW 6,000,000,000 for the total gross proceeds of KRW 6,600,000,000 on February 17, 2020. The transaction will include participation from Yama Medical Products Pte, Ltd for KRW 300,000,000, individual investor Jaehyun Jung for KRW 300,000,000, new investors E-world co.Ltd for KRW 3,000,000,000 and Havruta E Advisory Group Co., Ltd. for KRW 3,000,000,000. The bonds will be issued at 2% fixed coupon rate, 4% yield to maturity rate, and will mature on March 2, 2023. The 5th series bonds can be 100% converted into 75,000 common shares for 0.669% stake in the company at a fixed conversion price of KRW 8,000 per share and the 6th series bonds can be 100% converted into 750,000 common shares for 6.669% stake in the company at a fixed conversion price of KRW 8,000. The conversion period is from July 2, 2020 to March 1, 2023. The transaction has been approved by the board of directors of the company. The subscription date and the payment date is March 2, 2020.